A New Era in Therapeutics: Current Status of RNA Interference-Based Drugs

RNA interference (RNAi) is a post-transcriptional gene silencing mechanism that regulates gene expression through sequence-specific degradation or translational inhibition of mRNA. Since its discovery, RNAi has emerged as a powerful therapeutic strategy due to its ability to selectively silence disease-causing genes that are often inaccessible to conventional small-molecule drugs. The clinical efficacy of RNAi technology is evidenced by the approval of multiple siRNA-based therapeutics for the treatment of various diseases. These include patisiran and vutrisiran for hereditary transthyretin amyloidosis, inclisiran for hypercholesterolemia, fitusiran for haemophilia A and B, givosiran for acute hepatic porphyria, and lumasiran and nedosiran for primary hyperoxaluria. Concurrently, a significant number of RNAi therapeutics are currently undergoing clinical trials for metabolic, cardiovascular, neurological, renal, pulmonary diseases and oncological area. Despite these advances, the clinical translation of RNAi therapeutics is limited by several challenges, including off-target effects, immune activation, and difficulties associated with efficient and targeted delivery. Ongoing research focuses on improving siRNA design, chemical modification, and delivery strategies in order to enhance specificity, reduce immunogenicity, and achieve effective delivery to target tissues. In conclusion, RNA interference has become more significant and expanding therapeutic approach with considerable implications for future drug development.

Authors

Institutions

Publication Details

Journal
Pharmata
Published
2026-11-13
DOI
https://doi.org/10.62425/pharmata.1905266
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A New Era in Therapeutics: Current Status of RNA Interference-Based Drugs

Gökçen Telli, Lina Köylüoğlu
3 links
Pharmata
RNA Interference and Gene Delivery
article

A New Era in Therapeutics: Current Status of RNA Interference-Based Drugs

Gökçen Telli, Lina Köylüoğlu
article en

Abstract

RNA interference (RNAi) is a post-transcriptional gene silencing mechanism that regulates gene expression through sequence-specific degradation or translational inhibition of mRNA. Since its discovery, RNAi has emerged as a powerful therapeutic strategy due to its ability to selectively silence disease-causing genes that are often inaccessible to conventional small-molecule drugs. The clinical efficacy of RNAi technology is evidenced by the approval of multiple siRNA-based therapeutics for the treatment of various diseases. These include patisiran and vutrisiran for hereditary transthyretin amyloidosis, inclisiran for hypercholesterolemia, fitusiran for haemophilia A and B, givosiran for acute hepatic porphyria, and lumasiran and nedosiran for primary hyperoxaluria. Concurrently, a significant number of RNAi therapeutics are currently undergoing clinical trials for metabolic, cardiovascular, neurological, renal, pulmonary diseases and oncological area. Despite these advances, the clinical translation of RNAi therapeutics is limited by several challenges, including off-target effects, immune activation, and difficulties associated with efficient and targeted delivery. Ongoing research focuses on improving siRNA design, chemical modification, and delivery strategies in order to enhance specificity, reduce immunogenicity, and achieve effective delivery to target tissues. In conclusion, RNA interference has become more significant and expanding therapeutic approach with considerable implications for future drug development.

PharmataVol. 6(3)
Hacettepe University (TR)
Good health and well-being
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon